Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs

CNS Drugs
Maria P Amato, Emilio Portaccio

Abstract

In recent decades, pregnancy-related issues in multiple sclerosis (MS) have received growing interest. MS is more frequent in women than in men and typically starts during child-bearing age. An increasing number of disease-modifying drugs (DMDs) for the treatment of MS are becoming available. Gathering information on their influences on pregnancy-related issues is of crucial importance for the counselling of MS patients. As for the immunomodulatory drugs (interferons and glatiramer acetate), accumulating evidence points to the relative safety of pregnancy exposure in terms of maternal and foetal outcomes. In case of higher clinical disease activity before pregnancy, these drugs could be continued until conception. As for the 'newer' drugs (fingolimod, natalizumab, teriflunomide, dimethyl fumarate and alemtuzumab), the information is more limited. Whereas fingolimod and teriflunomide are likely associated with an increased risk of foetal malformations, the effects of natalizumab, dimethyl fumarate and alemtuzumab still need to be ascertained. This article provides a review of the available information on the use of DMDs during pregnancy, with a specific focus on fertility, foetal development, delivery and breast-feeding.

References

Jun 1, 1989·The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses·M E Dewis, N G Thornton
Nov 23, 1985·British Medical Journal·A R WatsonJ Bain
Nov 1, 1994·Acta Neurologica Scandinavica·E StenagerK Jensen
Feb 1, 1995·Brain : a Journal of Neurology·B Runmarker, O Andersen
Nov 1, 1994·Archives of Neurology·A D SadovnickD W Paty
Jun 1, 1997·Brain : a Journal of Neurology·T Wei, S L Lightman
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L MeistrichF B Hagemeister
Jul 31, 1998·The New England Journal of Medicine·C ConfavreuxT Moreau
Jan 5, 2000·Multiple Sclerosis : Clinical and Laboratory Research·M ZorzonG Cazzato
Sep 11, 2001·Multiple Sclerosis : Clinical and Laboratory Research·M W NortvedtH I Nyland
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Oct 21, 2003·World Journal of Urology·G R DohleR F A Weber
Oct 30, 2003·Multiple Sclerosis : Clinical and Laboratory Research·E PortaccioM P Amato
Mar 3, 2004·Birth Defects Research. Part A, Clinical and Molecular Teratology·Dario PaladiniPasquale Martinelli
May 8, 2004·Brain : a Journal of Neurology·Sandra VukusicUNKNOWN Pregnancy In Multiple Sclerosis Group
Aug 26, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Diane Borello-FranceTracy W Cannon
Dec 14, 2004·Journal of Neurology·P RieckmannUNKNOWN Multiple Sclerosis Therapy Consensus Group
Sep 28, 2005·Neurology·Emmanuelle Waubant, A Dessa Sadovnick
Oct 12, 2005·Neurology·R A MarrieT Vollmer
Oct 26, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P S SørensenUNKNOWN EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Apr 28, 2006·Acta Neurologica Scandinavica. Supplementum·J DahlN E Gilhus
Sep 15, 2006·The New England Journal of Medicine·Steffen Massberg, Ulrich H von Andrian
Sep 26, 2006·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·P CavallaA Revelli
Oct 21, 2006·Lancet Neurology·Sarah-Michelle OrtonUNKNOWN Canadian Collaborative Study Group
Jan 18, 2007·Neurotoxicology·M De SantisA Caruso
Jul 9, 2008·Neurology·Alvaro Alonso, Miguel A Hernán
Aug 15, 2008·Multiple Sclerosis : Clinical and Laboratory Research·E CoccoUNKNOWN FEMIMS Group
Oct 31, 2008·Lancet·Alastair Compston, Alasdair Coles
Feb 12, 2009·Onkologie·Anne K BaumgärtnerS Pildner von Steinburg
Mar 19, 2009·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Nancy G WehnerJanet Clarke
Mar 21, 2009·Multiple Sclerosis : Clinical and Laboratory Research·N Fernández LiguoriA Villa
Jun 10, 2009·Archives of Neurology·Annette Langer-GouldLorene M Nelson

❮ Previous
Next ❯

Citations

Mar 12, 2016·Multiple Sclerosis International·Saneea AlmasThomas Hale
Nov 14, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Ø TorkildsenL Bø
Jun 5, 2016·Continuum : Lifelong Learning in Neurology·Michelle Fabian
Jul 15, 2016·Expert Opinion on Biological Therapy·Sirin GandhiRobert Zivadinov
Nov 11, 2016·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Trygve Holmøy, Øivind Torkildsen
Dec 23, 2016·Immunotherapy·Serena DelbuePasquale Ferrante
Jun 24, 2017·Expert Opinion on Drug Safety·Marinella ClericoLuca Durelli
May 3, 2016·Therapeutic Advances in Neurological Disorders·Patricia K Coyle
Apr 7, 2018·Expert Opinion on Biological Therapy·Laura DumitrescuRadu Tanasescu
Mar 4, 2018·Cold Spring Harbor Perspectives in Medicine·Afsaneh Shirani, Olaf Stüve
Mar 29, 2019·The Medical Journal of Australia·Anneke Van Der WaltVilija Jokubaitis
May 17, 2019·Expert Review of Neurotherapeutics·Laura De GiglioCarlo Pozzilli
Feb 14, 2018·Neurology·Emilio PortaccioUNKNOWN MS Study Group of the Italian Neurological Society
Feb 14, 2018·Neurology·Emilio PortaccioUNKNOWN MS Study Group of the Italian Neurological Society
Jan 31, 2018·Neurology. Neuroimmunology and Neuroinflammation·Iris KleerekooperJoep Killestein
Aug 21, 2019·Expert Opinion on Drug Safety·Clara G ChisariFrancesco Patti
Apr 24, 2019·Biomedicines·Kelly Tisovic, Lilyana Amezcua
Jan 13, 2017·Multiple Sclerosis International·Raed AlroughaniSaeed Bohlega
Aug 5, 2017·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Maria Pia AmatoGiancarlo Comi
Jun 4, 2020·Hormones : International Journal of Endocrinology and Metabolism·Maria AnagnostouliGeorge Chrousos
Aug 3, 2020·Journal of Molecular Neuroscience : MN·Niyousha SadeghpourVahid Shaygannejad
Aug 31, 2020·International Journal of MS Care·Mary Filipi, Samantha Jack
Mar 13, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Claudia MassarottiPaola Anserini
May 18, 2021·Frontiers in Neurology·Simona BonavitaDominic Jack
Jul 1, 2021·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Hilde NorborgStig Wergeland
Aug 14, 2021·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Borros M Arneth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.